Treatment with olanzapine, fluoxetine and olanzapine/fluoxetine alters citrate synthase activity in rat brain

Neuroscience Letters

Volumn 487, Issue 3, 2011, Pages 278-281

  Agostinho, Fabiano R ^a   Réus, Gislaine Z ^a   Stringari, Roberto B ^a   Ribeiro, Karine F ^a   Ferraro, Ana K ^a   Benedet, Joana ^a   Rochi, Natália ^a   Scaini, Giselli ^a   Streck, Emílio L ^a   Quevedo, João ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Citrate synthase; Fluoxetine; Mood disorders; Olanzapine

Indexed keywords

CITRATE SYNTHASE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; OLANZAPINE;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CEREBELLUM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; ENERGY METABOLISM; ENZYME ACTIVITY; HIPPOCAMPUS; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ANIMALS; BENZODIAZEPINES; BRAIN; CITRATE (SI)-SYNTHASE; FLUOXETINE; MALE; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS;

EID: 78650443612     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.10.037     Document Type: Article

References (42)

1. Agostinho F.R., Scaini G., Ferreira G.K., Jeremias I.C., Réus G.Z., Rezin G.T., Castro A.A., Zugno A.I., Quevedo J., Streck E.L. Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain. Brain Res. Bull. 2009, 80:337-340.
2. Belmaker R.H. Bipolar disorder. New Engl. J. Med. 2004, 351:476-486.
3. Benazzi F., Berk M., Frye M.A., Wang W., Barraco A., Tohen M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. J. Clin. Psychiatry 2009, 70:1424-1431.
4. Calabrese V., Scapagnini G., Giuffrida-Stella A.M., Bates T.E., Clark J.B. Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem. Res. 2001, 26:739-764.
5. Corrêa C., Amboni G., Assis L.C., Kapczinski F., Streck E.L., Quevedo J. Effects of lithium and valproate on hippocampus citrate synthase activity in an animal model of mania. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31:887-891.
6. Davis L., Bartolucci A., Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J. Affect. Disord. 2005, 85:259-266.
7. Dodd S., Horgan D., Malhi G., Berk M. To combine or not to combine? A literature review of antidepressant combination therapy. J. Affect. Disord. 2005, 89:1-11.
8. Dubrovsky B.O. Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2005, 29:169-192.
9. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59:1116-1127.
10. Fava M. New approaches to the treatment of refractory depression. J. Clin. Psychiatry 2000, 61:26-32.
11. Ferretti V., Roullet P., Sargolini F., Rinald A., Perri V., Del Fabbro M., Constantini V.J., Annese V., Scesa G., De Stefano M.E., Oliverio A., Mele A. Ventral striatal plasticity and spatial memory. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7945-7950.
12. Gokce O., Runne H., Kuhn A., Luthi-Carter R. Short-term striatal gene expression responses to brain-derived neurotrophic factor are dependent on MEK and ERK activation. PLoS One 2009, 4:5292.
13. Hall J., Whalley H.C., Marwick K., Mckirdy J., Sussmann J., Romaniuk L., Johnstone E.C., Wan H.I., Mclntosh A.M., Lawrie S.M. Hippocampal function in schizophrenia and bipolar disorder. Psychol. Med. 2009, 7:1-10.
14. Hassel S., Almeida J.R., Kerr N., Naus S., Ladouceur C.D., Fissell K., Kupfer D.J., Phillips M.L. Elevated striatal and decreased dorsolateral prefrontal cortical activity in response to emotional stimuli in euthymic bipolar disorder: no associations with psychotropic medication load. Bipolar Disord. 2008, 10:916-927.
15. Hirschfeld R.M., Montgomery S.A., Aguglia E. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J. Clin. Psychiatry 2002, 63:826-837.
16. Kato T., Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2000, 2:180-190.
17. Konradi C., Eaton M., MacDonald M.L., Walsh J., Benes F.M., Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch. Gen. Psychiatry 2004, 61:300-308.
18. Kupfer D.J. The increasing medical burden in bipolar disorder. JAMA 2005, 293:2528-2530.
19. Lowry O.H., Rosebrough N.J., Farr A.L., Randal R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-267.
20. Lucca G., Comim C.M., Valvossori S.S., Réus G.Z., Vuolo F., Petronilho F., Gaviollo E.C., Dal-Pizzol F., Quevedo J. Increased oxidative stress in submitochondrial particles into the brain of rats submitted to the chronic mild stress paradigm. J. Psychiatr. Res. 2009, 43:864-869.
21. Mann J.J. The medical management of depression. New Engl. J. Med. 2005, 353:1819-1834.
22. Marais L., Stein D.J., Daniels W.M. Exercise increases BDNF levels in the striatum and decreases depressive-like behavior in chronically stressed rats. Metab. Brain Dis. 2009, 24:587-797.
23. Marco R., Pestaña A., Sebastian J., Sols A. Oxaloacetate metabolic crossroads in liver. Enzyme compartmentation and regulation of gluconeogenesis. Mol. Cell. Biochem. 1974, 3:53-70.
24. Marx C., Shampine L., Khisti R., Trost W.T., Bradford D.W., Grobin A.C., Massing M.W., Madison R.D., Butterfield M., Lieberman J., Morrow L. Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnenolone and peripheral deoxycorticosterone: implications for therapeutic actions. Pharmacol. Biochem. Behav. 2006, 84:609-617.
25. Matthews J.D., Bottonari K.A., Polania L.M. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J. Clin. Psychiatry 2002, 63:1164-1170.
26. Molina-Hernández M., Téllez-Alcántra N.P., Oliveira-Lopez J.I., Jaramillo M.T. Olanzapine plus 17-β estradiol produce antidepressant-like actions in rats forced to swim. Pharmacol. Biochem. Behav. 2009, 93:491-497.
27. Morishita S. Clonazepam as a therapeutic adjunct to improve the management of depression: a brief review. Hum. Psychopharmacol. 2009, 24:191-198.
28. Mueller T.I., Leon A.C., Keller M.B., Solomon D.A., Endicott J., Coryell W., Warshaw M., Maser J.D. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am. J. Psychiatry 1999, 156:1000-1006.
29. Müller-Oerlinghausen B., Roggenbach J. Bipolar disorder. Lancet 2002, 359:241-247.
30. Nelson G., Hall G.B., Forchuk C. Current and preferred housing of psychiatric consumers/survivors. Can. J. Commun. Ment. Health 2003, 22:5-19.
31. Nemeroff C.B. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J. Psychiatr. Res. 2007, 41:189-206.
32. Nestler E.J., Gould E., Manji H., Buncan M., Duman R.S., Greshnfeld H.K., Hen R., Koester S., Lederhendler I., Meaney M., Robbins T., Winsky L., Zalcman S. Preclinical models: status of basic research in depression. Biol. Psychiatry 2002, 52:503-528.
33. Rezin G.T., Amboni G., Zugno A.I., Quevedo J., Streck E.L. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res. 2009, 34:1021-1029.
34. Scaini G., Santos P.M., Benedet J., Rochi N., Gomes L.M., Borges L.S., Rezin G.T., Pezente D.P., Quevedo J., Streck E.L. Evaluation of Krebs cycle enzymes in the brain of rats after chronic administration of antidepressants. Brain Res. Bull. 2010, 82:224-227.
35. Schatzberg A.F. New approaches to managing psychotic depression. J. Clin. Psychiatry 2003, 64:19-23.
36. Shelton R.C., Tollefson G.D., Tohen M., Stahl S., Gannon K.S., Jacobs T.G., Buras W.R., Bymaster F.P., Zhang W., Spencer K.A., Feldman P.D., Meltzer H.Y. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry 2001, 158:131-134.
37. Shepherd D., Garland P.B. The kinetic properties of citrate synthase from rat liver mitochondria. Biochem. J. 1969, 114:597-610.
38. Streck E.L., Amboni G., Scaini G., Di-Pietro P.B., Rezin G.T., Valvassori S.S., Luz G., Kapcinski F., Quevedo J. Brain creatine kinase activity in an animal model of mania. Life Sci. 2008, 82:424-429.
39. Tamayo J.M., Sutton V.K., Mattei M.A., Diaz B., Jamal H.H., Vieta E., Zarate C.A., Fumero I., Tohen M. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J. Clin. Psychopharmacol. 2009, 29:358-361.
40. Ustun T.B., Ayuso-Mateos J.L., Chatterji S., Mathers C., Murray C.J. Global burden of depressive disorders in the year 2000. Braz. J. Psychiatry 2004, 84:386-392.
41. Uzunov D.P., Cooper T.B., Costa E., Guidotti A. Fluoxetine elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:12599-12604.
42. Valvassori S.S., Petronilho F.C., Réus G.Z., Steckert A.V., Oliveira V.B.M., Boeck C.R., Kapczinski F., Dal-Pizzol F., Quevedo J. Effect of N-acetylcysteine and/or deferoxamine on oxidative stress and hyperactivity in an animal model of mania. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2008, 32:1064-1068.